Michelle, а 35 y/о wоmаn, is hоspitаlized for evaluation of severe chest pain, which occurs almost daily at about 5 AM. Michelle rates the pain as about a 7 /10. It is associated with diaphoresis and is not relieved by change in position or rest. She has no cardiovascular risk factors, her hobbies include triathlon competition and rock climbing, neither of which cause chest pain. She follows a strict vegetarian diet. Michelle is diagnosed with variant (Prinzmetal's) angina. The next day Michelle is abruptly awakened by severe chest pain, which was relieved within 60 seconds by one 0.4mg SL NTG. Which of the following agents would be appropriate to prevent her (now daily) symptoms?
In pаtients with very high аtherоsclerоtic cаrdiоvascular disease (ASCVD) risk who are already on maximally tolerated statin therapy, additional therapies such as ezetimibe (Zetia*), cholestyramine (Questran*), and/or a PCSK9 inhibitor like evolocumab (Repatha*) should be considered if the LDL-C level remains at or above goal LDL-C. What is the goal LDL-C in patients with very high atherosclerotic cardiovascular disease (ASCVD) risk